Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 9/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14638745 | 1.00 | CYP1A1 (0.42) | CYP1A1CYP1B1MAOBALDH1A1LMNA | |
| SCHEMBL14638863 | 0.86 | NOTUM (0.41) | CYP1A1CYP1B1ALDH1A1LMNAGAA | |
| SCHEMBL14638864 | 0.86 | NOTUM (0.41) | CYP1A1CYP1B1ALDH1A1LMNAGAA | |
| SCHEMBL15999784 | 0.82 | ALDH1A1 (0.46) | MAOBALDH1A1LMNAGAAMAPT | |
| SCHEMBL15999788 | 0.82 | ALDH1A1 (0.38) | ALDH1A1LMNAGAAMAPTCES2 | |
| SCHEMBL14639350 | 0.81 | CA1 (0.46) | ALDH1A1LMNAMAPTCES2CES1 | |
| SCHEMBL14639202 | 0.81 | ALDH1A1 (0.37) | ALDH1A1MAPTCXCL12 | |
| SCHEMBL14638624 | 0.81 | ALDH1A1 (0.37) | ALDH1A1MAPTCXCL12 | |
| SCHEMBL14638790 | 0.81 | SMN1; SMN2 (0.43) | MAOBALDH1A1LMNAGAAMAPT | |
| SCHEMBL14639274 | 0.81 | ALDH1A1 (0.40) | MAOBALDH1A1LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249199-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | HEALTH RESEARCH, INC. (US) | 2014-09-04 | — | — | US | claimed |
| WO-2013012998-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | EMORY UNIVERSITY (US) | 2013-01-24 | — | — | WO | claimed |
| US-10093609-B2 | TAK1 kinase inhibitors, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170369417-A1 | TAK1 Kinase Inhibitors, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-28 | — | — | US | disclosed |
| US-9751825-B2 | TAK1 kinase inhibitors, compositions, and used related thereto | EMORY UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751825-B2 | TAK1 kinase inhibitors, compositions, and used related thereto | EMORY UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20140249199-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | HEALTH RESEARCH, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249199-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | HEALTH RESEARCH, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013012998-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | EMORY UNIVERSITY (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012998-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | EMORY UNIVERSITY (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093609-B2 | TAK1 kinase inhibitors, compositions, and uses related thereto | TAB1, MAP3K1, MAP3K6 | CYP1A1 2903/4885CYP1B1 2948/4885MAOB 3579/4885 |
| US-20140249199-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | TAB1, MAP3K1, MAP3K6 | CYP1A1 2830/4885CYP1B1 2994/4885MAOB 3690/4885 |
| US-20170369417-A1 | TAK1 Kinase Inhibitors, Compositions, and Uses Related Thereto | TAB1, MAP3K1, MAP3K6 | CYP1A1 2903/4885CYP1B1 2948/4885MAOB 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.